UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or other jurisdiction o ...

Q4 2023 Earnings Presentation February 20th, 2024 Getting patients back to the things that matter. Joe Woody Michael Greiner Chief Executive Officer Senior Vice President, CFO & Chief Transformation Officer ...

ALPHARETTA, Ga., Feb. 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year 2023 on Tuesday, Feb. 20 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer.To join the live conferen ...

Q3 2023 Earnings Presentation November 1st, 2023 Getting patients back to the things that matter. Joe Woody Michael Greiner Chief Executive Officer Senior Vice President, CFO & Chief Transformation Officer ...

Avanos Medical Inc. (NYSE:AVNS) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy and Corporate Development Joseph Woody - CEO Michael Greiner - Senior VP, CFO and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Kristen Stewart - CL King Daniel Stauder - JMP Securities Operator Good morning, and welcome to Avanos' Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Inst ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (Sta ...

Avanos Medical Inc. (NYSE:AVNS) Q2 2023 Results Conference Call August 9, 2023 9:00 AM ET Company Participants Joe Woody - CEO and Director Scott Galovan - Vice President of Strategy and Corporate Development Michael Greiner - Senior VP, CFO and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Kristen Stewart - CL King Daniel Stauder - JMP Securities Operator Good morning, everyone, and welcome to the Avanos Second Quarter 2023 Earnings Conference Call. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State or ...

Avanos Medical, Inc. (NYSE:AVNS) Q1 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants Scott Galovan - SVP, Strategy and M&A Joe Woody - CEO Michael Greiner - SVP, CFO, and Chief Transformation Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Drew Ranieri - Morgan Stanley Operator Good morning and welcome to the Avanos Q1 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (State o ...